These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Frew AJ; Powell RJ; Corrigan CJ; Durham SR; J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133 [TBL] [Abstract][Full Text] [Related]
16. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Powell RJ; Frew AJ; Corrigan CJ; Durham SR Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551 [TBL] [Abstract][Full Text] [Related]
17. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase. Hellkvist L; Hjalmarsson E; Weinfeld D; Dahl Å; Karlsson A; Westman M; Lundkvist K; Winqvist O; Georén SK; Westin U; Cardell LO Allergy; 2022 Mar; 77(3):883-896. PubMed ID: 34379802 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Safety, Efficacy, and Compliance of Intralymphatic Immunotherapy for Allergic Rhinoconjunctivitis: A Systematic Review and Meta-Analysis. Wang W; Wang X; Wang H; Wang X Int Arch Allergy Immunol; 2023; 184(8):754-766. PubMed ID: 37105134 [TBL] [Abstract][Full Text] [Related]
19. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis. Serrano E; Wahn HU; Didier A; Bachert C Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122 [TBL] [Abstract][Full Text] [Related]
20. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. Klimek L; Schendzielorz P; Pinol R; Pfaar O Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]